Tirzepatide (TZP) was associated with improved metabolic parameters and gonadal hormone levels in male patients with obesity and metabolic hypogonadism, according to findings of an Italian pilot study presented at ENDO 2025. AACE President Scott D. Isaacs, MD, FACP, FACE, noted the findings reinforce that weight loss can effectively reverse obesity-associated hypogonadism and that the hormonal improvements are primarily a result of weight reduction. He added that whether tirzepatide has direct effects on testosterone independent of weight loss remains unknown, and that longer-term data are needed. Learn more by reading the article on MedCentral.